Capital Fund Management S.A. Purchases New Position in Enovis Corporation $ENOV

Capital Fund Management S.A. acquired a new position in shares of Enovis Corporation (NYSE:ENOV) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 53,642 shares of the company’s stock, valued at approximately $1,682,000. Capital Fund Management S.A. owned approximately 0.09% of Enovis at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Humankind Investments LLC grew its holdings in shares of Enovis by 8.6% in the 1st quarter. Humankind Investments LLC now owns 5,688 shares of the company’s stock worth $217,000 after purchasing an additional 452 shares during the last quarter. US Bancorp DE grew its stake in Enovis by 2.5% during the first quarter. US Bancorp DE now owns 19,031 shares of the company’s stock worth $727,000 after buying an additional 462 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Enovis by 6.1% during the second quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock worth $272,000 after buying an additional 495 shares during the last quarter. Wedge Capital Management L L P NC increased its holdings in shares of Enovis by 0.3% during the second quarter. Wedge Capital Management L L P NC now owns 162,977 shares of the company’s stock worth $5,111,000 after buying an additional 498 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in shares of Enovis by 2.7% in the second quarter. Janney Montgomery Scott LLC now owns 22,375 shares of the company’s stock valued at $702,000 after acquiring an additional 593 shares during the last quarter. 98.45% of the stock is owned by institutional investors.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $27.96 on Friday. The company has a current ratio of 2.22, a quick ratio of 1.16 and a debt-to-equity ratio of 0.66. Enovis Corporation has a 1-year low of $25.47 and a 1-year high of $49.38. The stock has a market capitalization of $1.60 billion, a P/E ratio of -1.18 and a beta of 1.52. The business has a 50-day moving average price of $30.52 and a two-hundred day moving average price of $30.77.

Enovis (NYSE:ENOV) last issued its earnings results on Monday, January 8th. The company reported $0.59 earnings per share (EPS) for the quarter. The company had revenue of $383.81 million for the quarter. Enovis had a negative net margin of 61.22% and a positive return on equity of 7.79%. Equities analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Buying and Selling at Enovis

In related news, CEO Damien Mcdonald acquired 6,457 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The stock was acquired at an average cost of $30.97 per share, with a total value of $199,973.29. Following the completion of the purchase, the chief executive officer directly owned 102,753 shares in the company, valued at approximately $3,182,260.41. This trade represents a 6.71% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John Kleckner acquired 2,468 shares of the company’s stock in a transaction that occurred on Tuesday, November 25th. The stock was bought at an average price of $30.32 per share, with a total value of $74,829.76. Following the acquisition, the insider directly owned 12,302 shares of the company’s stock, valued at $372,996.64. The trade was a 25.10% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 2.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ENOV. UBS Group decreased their price target on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Needham & Company LLC decreased their target price on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Canaccord Genuity Group reduced their price target on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Wells Fargo & Company raised their price objective on shares of Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $51.17.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.